



Genomic Health, Inc.  
Investor Relations Department  
301 Penobscot Dr.  
Redwood City, CA 94063  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: GHDX

Last Trade:	33.14
Trade Time:	4:00 PM ET Jun 26, 2017
Change:	-0.16  (-0.480%)
Day Range	32.90 - 33.51
52-Week Range	24.81 - 33.97
Volume	102,448


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

**Genomic Health, Inc.** (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 2, 2017*

[Genomic Health Presents Data Further Demonstrating Ability of Oncotype DX® Tests to Optimize Outcomes in Patients Across Cancer Types](#)

*May 30, 2017*

[Genomic Health Announces Presentation of Eight Oncotype DX® Studies at the 2017 American Society of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types](#)

*May 25, 2017*

[Genomic Health to Present at Jefferies 2017 Healthcare Conference](#)

*May 13, 2017*

[Prospective Oncotype DX® Genomic Prostate Score™ Test Data Presented at AUA and Published in Urology Establish Test's Ability to Increase Use and Persistence on Active Surveillance in Prostate Cancer Patients](#)

*May 12, 2017*

[Oncotype DX® Genomic Prostate Score™ \(GPS\) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease](#)

## Financials & Filings [\[ View all \]](#)

*Mar 15, 2017*

[Annual Report \(10-K\)](#)

*Apr 28, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 10, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 4, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 9, 2016*

[Quarterly Report \(10-Q\)](#)